Endometriosis Drugs Market Will Reach $1.92bn In 2020, According To New Visiongain Data

12 September 2018
Pharma

A new report by visiongain forecasts that the endometriosis drugs market will achieve sales of $1.92 billion worldwide in 2020. That pharma market will experience revenue growth from 2016 to 2026, adapting to driving and restraining forces – changes, opportunities and threats. That revenue prediction and others appear in Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of that Expanding Market for Treating a Prevalent Women’s Reproductive System Disorder.

Visiongain published that report in February 2016. That company is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand potentials of industries and markets in healthcare and other fields.

10% of women worldwide have endometriosis, giving high, rising demand for medicines. In 2014 Lupron was the leading product for revenue generation in the endometriosis drugs market, accounting for 8.9% of that world market. Visanne became the second-highest selling drug in the endometriosis medicines market. The top five endometriosis drugs accounted for 30.2% of the total market. In 2014 and 2015, the US formed the leading national market for endometriosis therapies. Japan held second place for revenue generation from endometriosis-treating drugs. Visiongain’s study predicts that India will form the fastest growing emerging market there from 2016 to 2026. In 2014 AbbVie was the leading company, in a market holding some of the world’s largest pharmaceutical developers, producers and marketers.

From 2016 endometriosis treatment will face challenges through healthcare reforms and budgetary restrictions, but will benefit from increasing awareness of that women’s disease. That industry will also benefit from the launch of new products, from strong R&D in 2016. Success of that market will depend on awareness programmes and increasing demand from women for treatment, with rising disease incidence and improving diagnosis methods. Those developments give opportunity for healthcare companies to gain success by launching novel medicines and medical devices to suit patients’ needs worldwide.

Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “Endometriosis is one of the most widespread chronic conditions in women. Current diagnostic and treatment strategies possess limitations, reportedly causing side effects and inconvenience to patients. Many pharmaceutical companies are developing novel medicines with different therapeutic targets for treating endometriosis. The need for advances in medical technologies for better diagnoses and treatment for endometriosis expands, giving opportunities for companies and healthcare providers. And better treatment of endometriosis depends on greater understanding of the disease in medical science and the pharma industry, as well as more awareness programmes by healthcare providers.”

That therapeutic segment holds promising R&D. The new gonadotropin-releasing hormone (GnRH) antagonist approach to treat endometriosis may take over from the present GnRH agonist drugs, the study notes. There exists great scope for new and improved medicines, benefiting pharma companies, healthcare providers and patients.

Visiongain’s new report predicts trends and revenues of the endometriosis drugs market from 2016 to 2026, also giving recent sales results. That analysis shows revenue forecasts at overall world, product and national level to 2026. It also discusses research and development and shows an interview with an authority on that prevalent women’s reproductive system disease.

Revenue predictions to 2026 appear for these five brands, with discussions and supporting data:

• Lupron
• Eligard
• Zoladex
• Depo-Provera
• Visanne.

At world level that study discusses and forecasts endometriosis medicine revenues overall and at national level from 2016 to 2026, covering these 11 leading countries:

• US
• Japan
• Germany, France, Italy, Spain, UK (EU5)
• China, Brazil, India, Russia (BRIC).

Visiongain’s new investigation also gives qualitative analysis of the endometriosis medicines market, including R&D discussions, SWOT analysis and PEST assessment. It assesses leading pharmaceutical companies, too, including these organisations:

• AbbVie
• Pfizer
• Bayer HealthCare
• AstraZeneca
• Astellas
• Takeda.

Endometriosis Drug Forecasts and R&D 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics, biotechnologies and outsourced services in drug development, sales and manufacturing.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1